影像生物标志物在糖尿病黄斑水肿中的研究进展

Research Progress of Imaging Biomarkers in Diabetic Macular Edema

糖尿病视网膜病变(DR)是一种常见的眼底疾病,而糖尿病黄斑水肿(DME)是导致DR患者视力障碍的主要原因。目前,玻璃体注射抗血管内皮生长因子(VEGF)是糖尿病黄斑水肿的一线治疗方法,然而不同患者术后视功能差异很大。随着眼科检测技术的进步,人们对DME术后视力的预测因素有了更全面的认识。本文就DME患者术后影像相关生物标志物进行综述,以期更有效地监测、管理DME患者,为临床预后提供理论依据。

Diabetes retinopathy (DR) is a common fundus disease, and diabetic macular edema (DME) is the main cause of visual impairment in DR Patients. At present, vitreous injection of anti-vascular en-dothelial growth factor (VEGF) is the first-line treatment for diabetic macular edema. However, postoperative visual function varies greatly among different patients. With advances in ophthalmic testing technology, the predictors of postoperative vision after DME have become more fully under-stood. This paper reviews the biomarkers related to postoperative imaging in patients with DME, in order to more effectively monitor and manage patients with DME and provide theoretical basis for clinical prognosis.